Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship

20-11-2023 | Fertility | Research

An exploration of testicular cancer survivors’ experience of ejaculatory dysfunction following retroperitoneal lymph node dissection—a sub-study of the PREPARE clinical trial

Authors: C. Conduit, A. D. Hutchinson, M. Leonard, S. O.’Haire, M. Moody, B. Thomas, I. Sim, W. Hong, G. Ahmad, N. Lawrentschuk, J. Lewin, B. Tran, H. M. Dhillon

Published in: Journal of Cancer Survivorship

Login to get access

Abstract

Purpose

Ejaculatory dysfunction secondary to retrograde ejaculation or anejaculation is a complication of retroperitoneal lymph node dissection (RPLND) for survivors of testicular cancer. We explored survivors’ experiences of ejaculatory dysfunction following RPLND.

Methods

In a sub-study of a single-arm phase 2 clinical trial (ACTRN12622000537752/12622000542796), participants reporting ejaculatory dysfunction ≥ 6 months following RPLND were invited to complete semi-structured interviews. Purposive sampling was used. Interviews continued until thematic saturation occurred, and codebook thematic analysis of interviews was performed.

Results

Of 58 individuals recruited to the trial, 33 (57%) reported ejaculatory dysfunction. Of these, 32 (97%) agreed to interview and 15 participated. Participants interviewed had median age 34 years (range 24–66), 12 (80%) in a long-term relationship with median time from surgery 36 months (range 11–112). Three overarching themes were identified. The first reflected the value of RPLND despite ejaculatory dysfunction. The second illuminated the impact(s) of ejaculatory dysfunction closely mapped to life stage, with flow-on impacts to fertility, sex, psychological wellbeing and communication. The third reflected information needs.
Fertility was a substantial source of concern for some participants. Ejaculatory dysfunction had no effect on sex for some, whilst for others, sex was less pleasurable. Some reported benefits. Few reported ejaculatory dysfunction challenged masculinity, confidence, or self-esteem.

Conclusions

Future research should examine interventions to reduce distress related to fertility, challenged masculinity and body image.

Implications for Cancer Survivors

Whilst most participants considered ejaculatory dysfunction to have little impact on their sexual function and relationships, some reported significant difficulties varying by life stage and relationship status.
Appendix
Available only for authorised users
Literature
1.
Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, et al. Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumour: a population-based study from the Swedish Norwegian testicular cancer group. Eur Urol Oncol. 2020;3(3):383–9.
2.
3.
Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006;13(10):1311–6. CrossRefPubMed
4.
Arafa M, El Tabie O. Medical treatment of retrograde ejaculation in diabetic patients: a hope for spontaneous pregnancy. J Sex Med. 2008;5(1):194–8. CrossRefPubMed
5.
Jefferys A, Siassakos D, Wardle P. The management of retrograde ejaculation: a systematic review and update. Fertil Steril. 2012;97(2):306–12. CrossRefPubMed
6.
Lu S, Cui Y, Li X, Zhang H, Hu J, Liu J, et al. Sperm retrieval in anejaculatory diabetic men who failed in drug treatment and penile vibratory stimulation during blood sugar under control. Andrologia. 2014;46(4):370–3. CrossRefPubMed
7.
Mehta A, Sigman M. Management of the dry ejaculate: a systematic review of aspermia and retrograde ejaculation. Fertil Steril. 2015;104(5):1074–81. CrossRefPubMed
8.
Shoshany O, Abhyankar N, Elyaguov J, Niederberger C. Efficacy of treatment with pseudoephedrine in men with retrograde ejaculation. Andrology. 2017;5(4):744–8. CrossRefPubMed
9.
Safarinejad MR. Midodrine for the treatment of organic anejaculation but not spinal cord injury: a prospective randomized placebo-controlled double-blind clinical study. Int J Impot Res. 2019;21(4):213–20. CrossRef
10.
Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, et al. Treatment of relapse of clinical stage I nonseminomatous germ cell tumors on surveillance. J Clin Oncol. 2019;37(22):1919–26. CrossRefPubMed
11.
Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister D. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol. 2017;28(2):362–7. CrossRefPubMed
12.
13.
Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am. 1977;4(3):509–21. CrossRefPubMed
14.
Nazareth I, Lewin J, King M. Sexual dysfunction after treatment for testicular cancer: a systematic review. J Psychosom Res. 2001;51(6):735–43. CrossRefPubMed
15.
Revenig L, Leung A, Hsiao W. Ejaculatory physiology and pathophysiology: assessment and treatment in male infertility. Transl Androl Urol. 2014;3(1):41–9. PubMedPubMedCentral
16.
17.
Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021;39(14):1563–74. CrossRefPubMedPubMedCentral
18.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57. CrossRefPubMed
19.
Brooks J, McCluskey S, Turley E, King N. The utility of template analysis in qualitative psychology research. Qual Res Psychol. 2015;12(2):202–22. CrossRefPubMed
20.
21.
22.
Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93(2):200–7. CrossRefPubMedPubMedCentral
23.
Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. JNCI. 2005;97(18):1354–65. CrossRefPubMed
24.
Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649–57. CrossRefPubMed
25.
Smith AB, King M, Butow P, Luckett T, Grimison P, Toner GC, et al. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psychooncology. 2013;22(11):2557–64. CrossRefPubMed
26.
Smith AB, Rutherford C, Butow P, Olver I, Luckett T, Grimison P, et al. A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psychooncology. 2018;27(4):1129–37. CrossRefPubMed
27.
Kvammen Ø, Myklebust T, Solberg A, Møller B, Klepp OH, Fosså SD, et al. Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: a population-based prospective cohort study. PLoS ONE. 2019;14(12):e0225942. CrossRefPubMedPubMedCentral
28.
29.
Hellesnes R, Myklebust T, Fosså SD, Bremnes RM, Karlsdottir Á, Kvammen Ø, et al. Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol. 2021;39(32):3561–73. CrossRefPubMed
30.
31.
Nappi L, Thi M, Adra N, Hamilton RJ, Leao R, Lavoie JM, et al. Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors. Eur Urol. 2021;79(1):16–9. CrossRefPubMed
32.
Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, et al. A new model to predict benign histology in residual retroperitoneal masses after chemotherapy in nonseminoma. Eur Urol Focus. 2018;4(6):995–1001. CrossRefPubMed
33.
Walter J, Lohman M, Kundu S, Xu S. A new fertility risk rating system for surgical, radiotherapy, and chemotherapy interventions used in testicular cancer. Transl Cancer Res. 2016;5:S778–81. CrossRef
34.
Moody JA, Ahmed K, Yap T, Minhas S, Shabbir M. Fertility managment in testicular cancer: the need to establish a standardized and evidence-based patient-centric pathway. BJU Int. 2019;123:160–72. CrossRefPubMed
35.
Skoogh J, Steineck G, Johansson B, Wilderäng U, Stierner U. Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up. BJU Int. 2013;111(8):1287–93. CrossRefPubMed
36.
Rincones O, Smith A, Naher S, Mercieca-Bebber R, Stockler M. An updated systematic review of quantitative studies assessing anxiety, depression, fear of cancer recurrence or psychological distress in testicular cancer survivors. Cancer Manag Res. 2021;13:3803–16. CrossRefPubMedPubMedCentral
37.
Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol. 1982;127(4):685–8. CrossRefPubMed
38.
Ochsenkühn R, Kamischke A, Nieschlag E. Imipramine for successful treatment of retrograde ejaculation caused by retroperitoneal surgery. Int J Androl. 1999;22(3):173–7. CrossRefPubMed
39.
Tomasi PA, Fanciulli G, Delitala G. Successful treatment of retrograde ejaculation with the alpha1-adrenergic agonist methoxamine: case study. Int J Impot Res. 2005;17(3):297–9. CrossRefPubMed
40.
Hsiao W, Deveci S, Mulhall JP. Outcomes of the management of post-chemotherapy retroperitoneal lymph node dissection-associated anejaculation. BJU Int. 2012;110(8):1196–200. CrossRefPubMed
41.
Metadata
Title
An exploration of testicular cancer survivors’ experience of ejaculatory dysfunction following retroperitoneal lymph node dissection—a sub-study of the PREPARE clinical trial
Authors
C. Conduit
A. D. Hutchinson
M. Leonard
S. O.’Haire
M. Moody
B. Thomas
I. Sim
W. Hong
G. Ahmad
N. Lawrentschuk
J. Lewin
B. Tran
H. M. Dhillon
Publication date
20-11-2023
Publisher
Springer US
Keyword
Fertility
Published in
Journal of Cancer Survivorship
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-023-01489-9

European Society for Medical Oncology Congress 2023

NSCLC Video

ESMO23: Non-small-cell lung cancer highlights

Watch the panel discussion

Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2.

Supported by: F. Hoffmann-La Roche Ltd.
Dr. Luis Paz-Ares
Prof. Solange Peters
Dr. Marina Garassino

ESMO23: Small-cell lung cancer highlights

SCLC Expert Interview

Cancer of Unknown Primary: Key results from ESMO 2023

Cancer of Unknown Primary Expert Interview

Tisotumab vedotin improves recurrent and metastatic cervical cancer survival

25-10-2023 Cervical Cancer News

EV-302 heralds practice change for advanced urothelial cancer

24-10-2023 Urothelial Cancer News

First-line selpercatinib supported for RET-mutant medullary thyroid cancer

23-10-2023 Thyroid Cancer News

» View more highlights on the ESMO 2023 hub page

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

Case-Based Insights: Oncology and Hematology Training Course

A 45-year-old female patient complains that she has been getting weaker and weaker for several months. She has no appetite and suffers from diarrhoea. Immunofixation shows monoclonal lambda light chains in the serum. What is your tentative diagnosis?

48/♀ with increasing spontaneous haematomas all over her body – Case 37

Case-Based Insights: Oncology and Hematology Training Course

A 48-year-old female patient feels listless and reports petechiae occurred for the first time. In the last 3 days, she had reportedly developed severe toothache and fever. The blood count shows severe pancytopenia. What are your first steps?

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

Case-Based Insights: Oncology and Hematology Training Course

The 49-year-old female patient presents with significant swelling of the right arm. She reports having been diagnosed with breast cancer 1½ years ago, followed by surgical removal of the tumour. She had then received chemotherapy and irradiation. How do you proceed?

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

Case-Based Insights: Oncology and Hematology Training Course

A 53-year-old man complains of increasing pain in the left anterior pelvis, which is described as movement-dependent with radiation into the left lower extremity. For several months, he had noticed bloody urine from time to time without pain during micturition. What are your suspicions?

Image Credits